MAP3K4激酶的作用和癌症中的双重作用
Yuxin Huang1, Guanwen Wang2, Ningning Zhang3
1Department of Breast Cancer Center, Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China.
Discover oncology
|April 3, 2024
概括
中原激活蛋白激酶激酶4 (MAP3K4) 调节细胞过程,如细胞亡和自. 这项研究回顾了MAP3K4K.
科学领域:
- 细胞信号传递途径 细胞信号传递途径
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 该MAPK通路对于细胞对环境刺激的反应至关重要.
- MAP3K4,一种氨酸/氨酸激酶,对亡,自,生长和发育至关重要.
- MAP3K4与像GADD45这样的蛋白质相互作用,影响细胞功能.
研究的目的:
- 提供MAP3K4.4的生理功能概述.
- 阐明MAP3K4在癌症中的双重作用,作为瘤促进剂和抑制剂.
- 探索由MAP3K4激活影响的多样化的下游途径.
主要方法:
- 对MAP3K4.4现有研究的文献综述.
- 分析MAP3K4与其他蛋白质的相互作用.
- 检查MAP3K4在各种细胞过程和疾病模型中的作用.
主要成果:
- MAP3K4与调节亡和自有关.
- MAP3K4与GADD45的相互作用会影响生物体的生长和发育.
- MAP3K4在瘤发生过程中表现出上下文依赖的作用,同时作为瘤基因和瘤抑制剂.
结论:
- MAP3K4具有不同的生理功能.
- 在癌症中MAP3K4的矛盾作用突显了它在瘤发生过程中的复杂参与.
- 需要进一步的研究才能充分理解MAP3K4在癌症治疗中的治疗潜力.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


